Literature DB >> 6353195

Regulation of ribonucleotide reductase activity in mammalian cells.

J G Cory, A Sato.   

Abstract

Mammalian ribonucleotide reductase catalyzes the rate-limiting for the de novo synthesis 2'-deoxyribonucleoside 5'-triphosphates. There is some suggestion that this step may also be the rate-limiting step of DNA synthesis. It is apparent that the level of the enzyme, ribonucleotide reductase, varies through the cell cycle and is highest in those tissues with the greatest proliferation rate. This increase in activity is associated with increased protein synthesis. The purified enzyme has been shown to be subject to strict allosteric regulation by the various nucleoside triphosphates and it has been proposed that allosteric regulation plays an important role in the level of ribonucleotide reductase activity which is expressed. All experimental data relating to this point, however, do not support the role of deoxyribonucleoside triphosphates as a major factor in determining cellular reductase activity during normal cell division. Several naturally occurring factors have been isolated from cells which lower ribonucleotide reductase activity in vitro. These factors have been found in tissues of low growth fraction and appear to be absent or low in tissues or high growth fraction such as tumor, regenerating liver and embryonic tissues. The expression of intracellular ribonucleotide reductase activity is therefore controlled at various levels and by various factors and the prevailing mode of regulation may vary throughout the cell cycle transverse and also in the various types of cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6353195     DOI: 10.1007/bf00225258

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  62 in total

1.  Allosteric regulation of calf thymus ribonucleoside diphosphate reductase.

Authors:  S Eriksson; L Thelander; M Akerman
Journal:  Biochemistry       Date:  1979-07-10       Impact factor: 3.162

2.  Inhibition of mammalian ribonucleotide reductase by a dinucleotide produced in eucaryotic cells.

Authors:  W H Lewis; D R McNaughton; S H Goh; H B LéJohn; J A Wright
Journal:  J Cell Physiol       Date:  1977-12       Impact factor: 6.384

3.  Functional regulation of mammalian ribonucleotide reductase.

Authors:  H L Elford
Journal:  Adv Enzyme Regul       Date:  1972

4.  Alterations leading to increased ribonucleotide reductase in cells selected for resistance to deoxynucleosides.

Authors:  M Meuth; H Green
Journal:  Cell       Date:  1974-12       Impact factor: 41.582

5.  Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.

Authors:  H L Elford; M Freese; E Passamani; H P Morris
Journal:  J Biol Chem       Date:  1970-10-25       Impact factor: 5.157

6.  Ribonucleotide reductase of rabbit bone marrow. I. Purification, properties, and separation into two protein fractions.

Authors:  S Hopper
Journal:  J Biol Chem       Date:  1972-05-25       Impact factor: 5.157

7.  Molecular mechanisms of liver regeneration. VII. Conversion of cytidine to deoxycytidine in rat regenerating livers.

Authors:  C D King; J L Van Lancker
Journal:  Arch Biochem Biophys       Date:  1969-02       Impact factor: 4.013

8.  Regulation of fungal ribonucleotide reductase by unusual dinucleotides.

Authors:  W H Lewis; D R McNaughton; H B LéJohn; J A Wright
Journal:  Biochem Biophys Res Commun       Date:  1976-07-12       Impact factor: 3.575

9.  Studies on ribonucleoside-diphosphate reductase in permeable animal cells. II. Catalytic and regulatory properties of the enzyme in mouse L cells.

Authors:  R Kucera; H Paulus
Journal:  Arch Biochem Biophys       Date:  1982-03       Impact factor: 4.013

10.  Possible regulation of ribonucleoside diphosphate reductase.

Authors:  K Ikenaka; M Fukushima; T Shirasaka; S Fkkjii
Journal:  Gan       Date:  1981-02
View more
  21 in total

1.  Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.

Authors:  Allyson J Ocean; Paul Christos; Joseph A Sparano; Dan Matulich; Andreas Kaubish; Abby Siegel; Max Sung; Maureen M Ward; Nancy Hamel; Igor Espinoza-Delgado; Yun Yen; Maureen E Lane
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-28       Impact factor: 3.333

2.  Ribonucleotide reductase subunit p53R2 regulates mitochondria homeostasis and function in KB and PC-3 cancer cells.

Authors:  Xiaochen Wang; Xiyong Liu; Lijun Xue; Keqiang Zhang; Mei-Ling Kuo; Shuya Hu; Bingsen Zhou; David Ann; Suzhan Zhang; Yun Yen
Journal:  Biochem Biophys Res Commun       Date:  2011-05-25       Impact factor: 3.575

3.  Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.

Authors:  Xiyong Liu; Lily Lai; Xiaochen Wang; Lijun Xue; Sofia Leora; Jun Wu; Shuya Hu; Keqiang Zhang; Mei-Ling Kuo; Lun Zhou; Hang Zhang; Yafan Wang; Yan Wang; Bingsen Zhou; Rebecca A Nelson; Shu Zheng; Suzhan Zhang; Peiguo Chu; Yun Yen
Journal:  Cancer Res       Date:  2011-03-17       Impact factor: 12.701

4.  Polyamine depletion increases cellular ribonucleotide levels.

Authors:  S M Oredsson; M Kanje; P S Mamont; J Wagner; O Heby
Journal:  Mol Cell Biochem       Date:  1986-04       Impact factor: 3.396

5.  A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.

Authors:  Mark H Kirschbaum; Paul Frankel; Timothy W Synold; Zhiliang Xie; Yun Yen; Leslie Popplewell; Robert Chen; Omar Aljitawi; Joseph M Tuscano; Kenneth K Chan; Edward M Newman
Journal:  Leuk Lymphoma       Date:  2016-02-19

6.  The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Authors:  Nadim Bou Zgheib; Yin Xiong; Douglas C Marchion; Elona Bicaku; Hye Sook Chon; Xiaomang Ba Stickles; Entidhar Al Sawah; Patricia L Judson; Ardeshir Hakam; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Christopher L Cubitt; Dung Tsa Chen; Johnathan M Lancaster
Journal:  Int J Oncol       Date:  2012-04-26       Impact factor: 5.650

7.  MicroRNA-1468-5p inhibits glioma cell proliferation and induces cell cycle arrest by targeting RRM1.

Authors:  Kuan Jiang; Tongle Zhi; Wenhui Xu; Xiupeng Xu; Weining Wu; Tianfu Yu; Er Nie; Xu Zhou; Zhongyuan Bao; Xin Jin; Junxia Zhang; Yingyi Wang; Ning Liu
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

8.  Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.

Authors:  T Szekeres; K Gharehbaghi; M Fritzer; M Woody; A Srivastava; B van't Riet; H N Jayaram; H L Elford
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.

Authors:  Ai-Guo Lu; Hao Feng; Pu-Xiong-Zhi Wang; Ding-Pei Han; Xue-Hua Chen; Min-Hua Zheng
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

10.  Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Authors:  Stephen I Shibata; James H Doroshow; Paul Frankel; Timothy W Synold; Yun Yen; David R Gandara; Heinz-Josef Lenz; Warren A Chow; Lucille A Leong; Dean Lim; Kim A Margolin; Robert J Morgan; George Somlo; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-26       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.